Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)
Mata, N. (Fundación Hipercolesterolemia Familiar)
Alonso, R. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau)
Padró, Teresa (Institut d'Investigació Biomèdica Sant Pau)
Fuentes, F. (Hospital Universitario Reina Sofía (Córdoba, Espanya))
Muñiz, O. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Pérez-Jiménez, F. (Hospital Universitario Reina Sofía (Córdoba, Espanya))
López-Miranda, J. (Hospital Universitario Reina Sofía (Córdoba, Espanya))
Díaz, J.L. (Hospital Abente y Lago)
Vidal, J.I. (Hospital de Lugo)
Barba, A. (Complejo Hospitalario Universitario de Albacete)
Piedecausa, M. (Hospital General Universitario de Elche)
Sánchez, J.F. (Hospital de Cáceres)
Irigoyen, L. (Hospital de Vitoria)
Guallar, E. (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Ordovas, J.M. (Tufts University)
Mata, P. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Universitat Autònoma de Barcelona

Data:	2011
Resum:	Abstract. Aim. Familial hypercholesterolemia (FH) patients are at high risk for premature coronary heart disease (CHD). Despite the use of statins, most patients do not achieve an optimal LDL-cholesterol goal. The aims of this study are to describe baseline characteristics and to evaluate Lipid Lowering Therapy (LLT) in FH patients recruited in SAFEHEART. Methods and Results. A cross-sectional analysis of cases recruited in the Spanish FH cohort at inclusion was performed. Demographic, lifestyle, medical and therapeutic data were collected by specific surveys. Blood samples for lipid profile and DNA were obtained. Genetic test for FH was performed through DNA-microarray. Data from 1852 subjects (47. 5% males) over 19 years old were analyzed: 1262 (68. 1%, mean age 45. 6 years) had genetic diagnosis of FH and 590 (31. 9%, mean age 41. 3 years) were non-FH. Cardiovascular disease was present in 14% of FH and in 3. 2% of non-FH subjects (P < 0. 001), and was significantly higher in patients carrying a null mutation compared with those carrying a defective mutation (14. 87% vs. 10. 6%, respectively, P < 0. 05). Prevalence of current smokers was 28. 4% in FH subjects. Most FH cases were receiving LLT (84%). Although 51. 5% were receiving treatment expected to reduce LDL-c levels at least 50%, only 13. 6% were on maximum statin dose combined with ezetimibe. Mean LDL-c level in treated FH cases was 186. 5 mg/dl (SD: 65. 6) and only 3. 4% of patients reached and LDL-c under 100 mg/dl. The best predictor for LDL-c goal attainment was the use of combined therapy with statin and ezetimibe. Conclusion: Although most of this high risk population is receiving LLT, prevalence of cardiovascular disease and LDL-c levels are still high and far from the optimum LDL-c therapeutic goal. However, LDL-c levels could be reduced by using more intensive LLT such as combined therapy with maximum statin dose and ezetimibe. © 2011 Mata et al; licensee BioMed Central Ltd.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Familial hypercholesterolemia ; Coronary artery disease ; LDL-receptor mutations ; LDL-c goal ; Combined therapy
Publicat a:	Lipids in Health and Disease, Vol. 10 (2011) , p. 94, ISSN 1476-511X

DOI: 10.1186/1476-511X-10-94
PMID: 21663647

7 p, 457.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats